380 related articles for article (PubMed ID: 27477529)
21. High Extratumoral Mast Cell Counts Are Associated with a Higher Risk of Adverse Prostate Cancer Outcomes.
Hempel Sullivan H; Heaphy CM; Kulac I; Cuka N; Lu J; Barber JR; De Marzo AM; Lotan TL; Joshu CE; Sfanos KS
Cancer Epidemiol Biomarkers Prev; 2020 Mar; 29(3):668-675. PubMed ID: 31932412
[TBL] [Abstract][Full Text] [Related]
22. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.
Cullen J; Rosner IL; Brand TC; Zhang N; Tsiatis AC; Moncur J; Ali A; Chen Y; Knezevic D; Maddala T; Lawrence HJ; Febbo PG; Srivastava S; Sesterhenn IA; McLeod DG
Eur Urol; 2015 Jul; 68(1):123-31. PubMed ID: 25465337
[TBL] [Abstract][Full Text] [Related]
23. Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up.
Faisal FA; Sundi D; Cooper JL; Humphreys EB; Partin AW; Han M; Ross AE; Schaeffer EM
Urology; 2014 Dec; 84(6):1434-41. PubMed ID: 25432835
[TBL] [Abstract][Full Text] [Related]
24. Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry.
Yuan J; Kensler KH; Hu Z; Zhang Y; Zhang T; Jiang J; Xu M; Pan Y; Long M; Montone KT; Tanyi JL; Fan Y; Zhang R; Hu X; Rebbeck TR; Zhang L
PLoS Genet; 2020 Feb; 16(2):e1008641. PubMed ID: 32059012
[TBL] [Abstract][Full Text] [Related]
25. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?
Sundi D; Ross AE; Humphreys EB; Han M; Partin AW; Carter HB; Schaeffer EM
J Clin Oncol; 2013 Aug; 31(24):2991-7. PubMed ID: 23775960
[TBL] [Abstract][Full Text] [Related]
26. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
Hamid AA; Gray KP; Huang Y; Bowden M; Pomerantz M; Loda M; Sweeney CJ
Eur Urol Oncol; 2019 Sep; 2(5):475-482. PubMed ID: 31411988
[TBL] [Abstract][Full Text] [Related]
27. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
Ahearn TU; Pettersson A; Ebot EM; Gerke T; Graff RE; Morais CL; Hicks JL; Wilson KM; Rider JR; Sesso HD; Fiorentino M; Flavin R; Finn S; Giovannucci EL; Loda M; Stampfer MJ; De Marzo AM; Mucci LA; Lotan TL
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26615022
[TBL] [Abstract][Full Text] [Related]
28. African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men.
Yamoah K; Deville C; Vapiwala N; Spangler E; Zeigler-Johnson CM; Malkowicz B; Lee DI; Kattan M; Dicker AP; Rebbeck TR
Urol Oncol; 2015 Feb; 33(2):70.e15-22. PubMed ID: 25304288
[TBL] [Abstract][Full Text] [Related]
29. Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy.
Jeong IG; Dajani D; Verghese M; Hwang J; Cho YM; Hong JH; Kim CS; Ahn H; Ro JY
Urol Oncol; 2016 Jan; 34(1):3.e9-14. PubMed ID: 26345648
[TBL] [Abstract][Full Text] [Related]
30. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
31. Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location.
Faisal FA; Sundi D; Tosoian JJ; Choeurng V; Alshalalfa M; Ross AE; Klein E; Den R; Dicker A; Erho N; Davicioni E; Lotan TL; Schaeffer EM
Eur Urol; 2016 Jul; 70(1):14-17. PubMed ID: 26443432
[TBL] [Abstract][Full Text] [Related]
32. Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.
Yamoah K; Johnson MH; Choeurng V; Faisal FA; Yousefi K; Haddad Z; Ross AE; Alshalafa M; Den R; Lal P; Feldman M; Dicker AP; Klein EA; Davicioni E; Rebbeck TR; Schaeffer EM
J Clin Oncol; 2015 Sep; 33(25):2789-96. PubMed ID: 26195723
[TBL] [Abstract][Full Text] [Related]
33. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.
Hashim D; Gonzalez-Feliciano AG; Ahearn TU; Pettersson A; Barber L; Pernar CH; Ebot EM; Isikbay M; Finn SP; Giovannucci EL; Lis RT; Loda M; Parmigiani G; Lotan T; Kantoff PW; Mucci LA; Graff RE
Int J Cancer; 2020 May; 146(10):2694-2702. PubMed ID: 31318977
[TBL] [Abstract][Full Text] [Related]
34. High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
Grupp K; Habermann M; Sirma H; Simon R; Steurer S; Hube-Magg C; Prien K; Burkhardt L; Jedrzejewska K; Salomon G; Heinzer H; Wilczak W; Kluth M; Izbicki JR; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Mod Pathol; 2014 Jan; 27(1):96-106. PubMed ID: 23887301
[TBL] [Abstract][Full Text] [Related]
35. PTEN and ERG expression in MRI-ultrasound guided fusion biopsy correlated with radical prostatectomy findings in men with prostate cancer.
Erickson AM; Lokman U; Lahdensuo K; Tornberg S; Visapaa H; Bergroth R; Santti H; Petas A; Rannikko AS; Mirtti T
Prostate; 2020 Sep; 80(13):1118-1127. PubMed ID: 32634262
[TBL] [Abstract][Full Text] [Related]
36. PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy.
Guedes LB; Tosoian JJ; Hicks J; Ross AE; Lotan TL
J Urol; 2017 Apr; 197(4):1054-1059. PubMed ID: 27693448
[TBL] [Abstract][Full Text] [Related]
37. Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison.
Ritch CR; Morrison BF; Hruby G; Coard KC; Mayhew R; Aiken W; Benson MC; McKiernan JM
BJU Int; 2013 Apr; 111(4 Pt B):E186-90. PubMed ID: 23107067
[TBL] [Abstract][Full Text] [Related]
38. Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease.
Powell IJ; Banerjee M; Novallo M; Sakr W; Grignon D; Wood DP; Pontes JE
Urology; 2000 Feb; 55(2):246-51. PubMed ID: 10688088
[TBL] [Abstract][Full Text] [Related]
39. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
[TBL] [Abstract][Full Text] [Related]
40. Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
Minner S; Lutz J; Hube-Magg C; Kluth M; Simon R; Höflmayer D; Burandt E; Tsourlakis MC; Sauter G; Büscheck F; Wilczak W; Steurer S; Schlomm T; Huland H; Graefen M; Haese A; Heinzer H; Jacobsen F; Hinsch A; Poos A; Oswald M; Rippe K; König R; Schroeder C
Prostate; 2019 Feb; 79(3):302-311. PubMed ID: 30430607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
